行情

ASND

ASND

Ascendis制药
NASDAQ

实时行情|Nasdaq Last Sale

139.13
-1.34
-0.95%
盘后: 139.13 0 0.00% 16:00 01/17 EST
开盘
140.15
昨收
140.47
最高
141.88
最低
136.67
成交量
21.68万
成交额
--
52周最高
142.94
52周最低
66.12
市值
66.42亿
市盈率(TTM)
-33.7399
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASND 新闻

  • 英国央行行长称:全球经济正陷入“流动性陷阱”
  • 新浪美股.6小时前
  • 弹劾案审讯开始在即 民主党人、特朗普律师提交主张
  • 新浪财经.6小时前
  • 利比亚输油管线和谈前被关闭 或加剧石油供应中断
  • 新浪财经.6小时前
  • 使用同一"排名最低"供应商 波音777X重现MAX安全问题
  • 新浪美股.6小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ASND 简况

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
展开

Webull提供Ascendis Pharma A/S的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。